Novo Nordisk could lose millions on discount dispute in US

The first round of a legal strife with US authorities concerning drug discounts for vulnerable Americans did not end favorably for Novo Nordisk. If the Danish giant keeps losing, the case could end up costing DKK 2bn (USD 307.3m) in lost revenue.

Photo: Novo Nordisk / PR

A strife concerning drugs for vulnerable or uninsured Americans could end up costing Danish pharmaceutical giant Novo Nordisk many millions of dollars.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs